Pursuant to the terms of the agreement, GSK will research a recombinant protein on the PER.C6 platform. Financial terms of the agreement were not disclosed.
Crucell’s PER.C6 technology platform has been developed for the large-scale manufacture of biopharmaceutical products such as recombinant proteins including monoclonal antibodies.
Ronald Brus, Crucell’s CEO, said: “We are very pleased to enter into this collaboration with GSK. This agreement further underscores the potential of our PER.C6 production technology for generating recombinant proteins.”
Karen King, president of DSM Biologics, said: “This agreement with GSK brings us closer to our mission of making PER.C6 technology a gold standard for industry use.”